Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 760 JPY 2.04% Market Closed
Market Cap: 133.8B JPY
Have any thoughts about
Torii Pharmaceutical Co Ltd?
Write Note

Cash Flow Statement

Cash Flow Statement
Torii Pharmaceutical Co Ltd

Rotate your device to view
Cash Flow Statement
Currency: JPY
Jun-2005 Dec-2005 Jun-2006 Dec-2006 Jun-2007 Dec-2007 Jun-2008 Dec-2008 Jun-2009 Dec-2009 Jun-2010 Sep-2010 Dec-2010 Mar-2011 Sep-2011 Mar-2012 Sep-2012 Mar-2013 Sep-2013 Mar-2014 Sep-2014 Dec-2014 Jun-2015 Dec-2015 Jun-2016 Dec-2016 Jun-2017 Dec-2017 Jun-2018 Dec-2018 Jun-2019 Dec-2019 Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023 Jun-2024
Operating Cash Flow
Net Income
(553)
(2 854)
(343)
(2 177)
(89)
463
286
487
(305)
130
(54)
1 241
(1 003)
(3 998)
433
5 054
5 661
2 929
3 399
5 133
4 473
3 781
6 281
5 258
5 033
4 056
4 174
6 373
6 113
3 030
37 687
37 700
3 038
4 225
3 883
4 767
5 636
5 722
4 607
5 593
7 029
Depreciation & Amortization
9
15
23
93
47
146
37
107
13
51
12
361
13
370
1 296
1 194
1 114
1 061
865
1 089
1 156
924
1 624
1 457
1 428
1 339
1 261
1 174
1 087
1 040
1 031
985
889
582
387
413
415
454
468
459
437
Other Non-Cash Items
(1)
16
(106)
(180)
15
(116)
(14)
(15)
39
100
6
(31)
28
21
(120)
(134)
(151)
(154)
(129)
(115)
265
284
272
(237)
(250)
(117)
(99)
(23)
(49)
1 950
(34 491)
(36 231)
883
470
(283)
(232)
(260)
(312)
(360)
(365)
(128)
Cash Taxes Paid
(799)
(1 146)
197
(384)
(333)
(250)
77
98
(834)
(1 193)
1 373
1 375
1 561
1 564
2 119
2 073
2 722
1 921
932
1 111
1 574
1 172
1 411
413
2 037
2 500
1 329
1 263
1 810
1 855
1 336
1 401
10 002
9 410
50
(21)
1 444
2 006
1 593
1 803
1 829
Cash Interest Paid
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
1
1
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
Change in Working Capital
59
(405)
1 125
2 096
418
641
(520)
(813)
(140)
257
(483)
509
(256)
494
(3 272)
(3 073)
(4 098)
(3 683)
(5 956)
(6 308)
(3 881)
(5 598)
(5 977)
(1 537)
(3 073)
(1 875)
(638)
(1 174)
(24)
2 239
49 819
40 045
(16 773)
(8 721)
(3 721)
(5 105)
(3 367)
(3 444)
(4 452)
(8 811)
(6 081)
Cash from Operating Activities
(486)
N/A
(3 228)
-564%
699
N/A
(168)
N/A
391
N/A
1 134
+190%
(211)
N/A
(234)
-11%
(393)
-68%
538
N/A
(519)
N/A
2 080
N/A
(1 218)
N/A
(3 113)
-156%
(1 663)
+47%
3 041
N/A
2 526
-17%
153
-94%
(1 623)
N/A
(201)
+88%
2 013
N/A
(609)
N/A
2 200
N/A
4 941
+125%
3 138
-36%
3 403
+8%
4 698
+38%
6 350
+35%
7 127
+12%
8 259
+16%
54 046
+554%
42 499
-21%
(11 963)
N/A
(3 444)
+71%
266
N/A
(157)
N/A
2 424
N/A
2 420
0%
263
-89%
(3 124)
N/A
1 257
N/A
Investing Cash Flow
Capital Expenditures
57
(153)
(276)
(738)
432
685
(74)
(25)
93
(91)
(98)
(292)
279
104
(703)
(683)
(1 238)
(1 350)
(795)
(811)
(1 119)
(884)
(1 551)
(1 484)
(1 156)
(760)
(867)
(789)
(745)
(675)
(615)
(546)
(344)
(411)
(492)
(374)
(358)
(281)
(184)
(216)
(167)
Other Items
3 392
5 306
(3 601)
(3 630)
2 503
3 272
(909)
(330)
(2 010)
(12 879)
(3 392)
(12 867)
(3 171)
(8 858)
(4 500)
3 834
3 167
2 224
20 100
18 517
(2 298)
1 383
2 283
2 441
2 140
2 121
1 200
(6 804)
(19 334)
(26 393)
(11 494)
2 645
89
8 036
5 967
(1 124)
(1 922)
(13 395)
(15 091)
(3 563)
(944)
Cash from Investing Activities
3 449
N/A
5 153
+49%
(3 877)
N/A
(4 368)
-13%
2 935
N/A
3 957
+35%
(983)
N/A
(355)
+64%
(1 917)
-440%
(12 970)
-577%
(3 490)
+73%
(13 159)
-277%
(2 892)
+78%
(8 754)
-203%
(5 203)
+41%
3 151
N/A
1 929
-39%
874
-55%
19 305
+2 109%
17 706
-8%
(3 417)
N/A
499
N/A
732
+47%
957
+31%
984
+3%
1 361
+38%
333
-76%
(7 593)
N/A
(20 079)
-164%
(27 068)
-35%
(12 109)
+55%
2 099
N/A
(255)
N/A
7 625
N/A
5 475
-28%
(1 498)
N/A
(2 280)
-52%
(13 676)
-500%
(15 275)
-12%
(3 779)
+75%
(1 111)
+71%
Financing Cash Flow
Net Issuance of Common Stock
0
0
0
1
0
0
0
0
0
1
0
0
0
(1)
(1)
0
0
0
0
(1)
(1)
0
0
(2)
(2)
(615)
(615)
(1)
(1)
0
0
(1)
(1)
8
0
0
0
0
0
0
0
Net Issuance of Debt
0
200
0
0
0
0
0
0
(20)
(58)
3
(14)
12
5
(31)
(21)
(17)
(48)
(119)
(185)
(280)
(277)
(433)
(334)
(374)
(315)
(237)
(198)
(122)
(85)
(85)
(85)
(85)
(85)
(131)
(198)
(265)
(348)
(344)
(293)
(326)
Cash Paid for Dividends
(113)
(170)
57
57
0
0
(114)
(170)
(113)
(198)
(28)
(28)
(85)
(85)
(1 132)
(1 132)
(1 132)
(1 132)
(1 132)
(1 132)
(1 132)
(1 132)
(1 697)
(1 245)
(1 359)
(1 358)
(1 352)
(1 346)
(1 346)
(1 346)
(1 346)
(1 347)
(1 347)
(1 347)
(1 348)
(1 348)
(1 348)
(1 348)
(2 809)
(3 540)
(3 372)
Other
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(1)
0
(1)
0
(1)
(2)
(1)
(3)
(1)
0
(1)
(1)
(1)
(1)
(1)
0
0
(1)
(1)
0
0
0
(2)
(3)
(2)
(2)
Cash from Financing Activities
(113)
N/A
30
N/A
57
+90%
58
+2%
0
N/A
0
N/A
(114)
N/A
(170)
-49%
(133)
+22%
(255)
-92%
(25)
+90%
(42)
-68%
(73)
-74%
(81)
-11%
(1 164)
-1 337%
(1 154)
+1%
(1 150)
+0%
(1 181)
-3%
(1 252)
-6%
(1 319)
-5%
(1 415)
-7%
(1 410)
+0%
(2 133)
-51%
(1 582)
+26%
(1 735)
-10%
(2 289)
-32%
(2 205)
+4%
(1 546)
+30%
(1 470)
+5%
(1 432)
+3%
(1 432)
N/A
(1 433)
0%
(1 433)
N/A
(1 425)
+1%
(1 471)
-3%
(1 546)
-5%
(1 613)
-4%
(1 698)
-5%
(3 156)
-86%
(3 835)
-22%
(3 700)
+4%
Change in Cash
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(22)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net Change in Cash
2 850
N/A
1 955
-31%
(3 121)
N/A
(4 478)
-43%
3 326
N/A
5 091
+53%
(1 308)
N/A
(759)
+42%
(2 443)
-222%
(12 687)
-419%
(4 034)
+68%
(11 121)
-176%
(4 183)
+62%
(11 948)
-186%
(8 052)
+33%
5 038
N/A
3 305
-34%
(154)
N/A
16 430
N/A
16 186
-1%
(2 819)
N/A
(1 520)
+46%
799
N/A
4 316
+440%
2 387
-45%
2 475
+4%
2 826
+14%
(2 789)
N/A
(14 422)
-417%
(20 241)
-40%
40 505
N/A
43 165
+7%
(13 651)
N/A
2 756
N/A
4 270
+55%
(3 201)
N/A
(1 469)
+54%
(12 954)
-782%
(18 168)
-40%
(10 738)
+41%
(3 554)
+67%
Free Cash Flow
Free Cash Flow
(429)
N/A
(3 381)
-688%
423
N/A
(906)
N/A
823
N/A
1 819
+121%
(285)
N/A
(259)
+9%
(300)
-16%
447
N/A
(617)
N/A
1 788
N/A
(939)
N/A
(3 009)
-220%
(2 366)
+21%
2 358
N/A
1 288
-45%
(1 197)
N/A
(2 418)
-102%
(1 012)
+58%
894
N/A
(1 493)
N/A
649
N/A
3 457
+433%
1 982
-43%
2 643
+33%
3 831
+45%
5 561
+45%
6 382
+15%
7 584
+19%
53 431
+605%
41 953
-21%
(12 307)
N/A
(3 855)
+69%
(226)
+94%
(531)
-135%
2 066
N/A
2 139
+4%
79
-96%
(3 340)
N/A
1 090
N/A

See Also

Discover More